Clene Inc

Officers & Directors

Clene Inc currently has 79 employees.

News about Clene Inc Key Personnel

Clene Inc. Prepares for Pivotal FDA Conference, Charting a Course Toward a Potential ALS Breakthrough,

Clene Inc. Taps into Potential ALS Breakthrough with FDA In-Person Meeting on CNM-Au8 Development
In a significant development for neurodegenerative disease treatment, Clene Inc. (Nasdaq: CLNN), along with its wholly owned subsidiary Clene Nanomedicine Inc. has been granted an in-person meeting with senior leadership at the U.S. Food and Drug Administration (FDA) to discuss its groundbreaking treatment for amyotrophic lateral sclerosis (ALS), CNM-Au8. Scheduled to take place before the end of November 2024, this meeting underscores the company s commitment to advancing its innovative approaches in the fight against ALS and potentially other neurodegenerative diseases.

The Context of Clene...

Business Description

Officers & Directors

CLNN Management Effectiveness

CLNN Revenue per Employee

CLNN Income per Employee

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.